Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis - Wikidata - wikimedia - TriplyDB

Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis

Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis

http://www.wikidata.org/entity/Q28740917

about

Systems immunology of human malaria Cerebrospinal fluid biomarkers of Alzheimer’s disease Breaking boundaries-coagulation and fibrinolysis at the neurovascular interface Applying computation biology and "big data" to develop multiplex diagnostics for complex chronic diseases such as osteoarthritis Cerebrospinal fluid biomarkers of neurovascular dysfunction in mild dementia and Alzheimer's disease A Subset of Cerebrospinal Fluid Proteins from a Multi-Analyte Panel Associated with Brain Atrophy, Disease Classification and Prediction in Alzheimer's Disease Drug Repositioning for Alzheimer's Disease Based on Systematic 'omics' Data Mining Persistent, long-term cerebral white matter changes after sports-related repetitive head impacts Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset Plasma biomarkers of brain atrophy in Alzheimer's disease Brain immune interactions and air pollution: macrophage inhibitory factor (MIF), prion cellular protein (PrP(C)), Interleukin-6 (IL-6), interleukin 1 receptor antagonist (IL-1Ra), and interleukin-2 (IL-2) in cerebrospinal fluid and MIF in serum diff Photoacoustic imaging of mesenchymal stem cells in living mice via silica-coated gold nanorods A novel Aβ-fibrinogen interaction inhibitor rescues altered thrombosis and cognitive decline in Alzheimer's disease mice Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease.Biomarkers in the Diagnosis and Prognosis of Alzheimer's Disease.Phosphorylated tau-Aβ42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid.Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort.Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer's disease.Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics.Machine learning and microsimulation techniques on the prognosis of dementia: A systematic literature review.Transcranial near-infrared laser therapy applied to promote clinical recovery in acute and chronic neurodegenerative diseases.Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview.A platelet protein biochip rapidly detects an Alzheimer's disease-specific phenotype Alterations of CSF cystatin C levels and their correlations with CSF Αβ40 and Αβ42 levels in patients with Alzheimer's disease, dementia with lewy bodies and the atrophic form of general paresis Cerebrovascular Biomarker Profile Is Related to White Matter Disease and Ventricular Dilation in a LADIS Substudy.Quantitative label-free proteomics for discovery of biomarkers in cerebrospinal fluid: assessment of technical and inter-individual variation.Biomarkers of central nervous system inflammation in infantile and juvenile gangliosidoses.Human apoE isoforms differentially regulate brain amyloid-β peptide clearance Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers.Central Nervous System and Peripheral Inflammatory Processes in Alzheimer's Disease: Biomarker Profiling Approach.Association of Pancreatic Polypeptide with Mild Cognitive Impairment Varies by APOE ε4 Allele.Cystatin C in Alzheimer's disease.Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease Identifying amyloid pathology-related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study.CSF complement 3 and factor H are staging biomarkers in Alzheimer's disease Multiplex assessment of a panel of 16 serum molecules for the differential diagnosis of Alzheimer's disease Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain.Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease.

P2860

Q21032488-7D178F6A-0ED3-4FC4-B757-DF9871230D34 Q22252572-54D966E4-0375-4659-8B6A-00BCB1277D08 Q26781646-A8BA9538-03F4-4F98-956A-ECC4DEF0CBC5 Q28076074-10E85589-FDA7-490F-A45A-FAC3442D84B9 Q28087176-1F6BAD52-1042-4D74-8828-443B33EAC00E Q28547333-79D1D53E-8DFE-4183-A12B-FFE1E2AE1FFB Q28555197-04298133-4606-428F-8E5D-51C993025B1B Q28659962-974071D2-543E-4D09-B427-4D09D9331548 Q28730795-0C689CB4-9ECD-4594-976C-4D5DFD61BFE5 Q28741028-940DA744-374A-48C0-AA33-202A7FD26889 Q30416813-6FB17DB8-053B-417D-AEFB-1BA7D4AB682C Q30457905-3F6A2F41-7AFB-4E97-B547-4C5A86FCF5DF Q30579707-891D19F8-0E0D-45CA-9862-CDDC0989EE35 Q30845482-6C572412-1716-45D3-911E-2F40C619EB63 Q30871982-8A9B77E7-B162-43B5-A8DF-3FBD0B8E034F Q33554802-055DAD67-D93F-43A6-A3EA-97B5B9A1268B Q33652456-2D644F79-4097-4B7B-B966-78BAC98E3B43 Q33745920-602F2E63-6609-474D-AC23-4B2EE40F9577 Q33769278-EB5E4246-319F-429E-B9D4-8A3ED65DD41E Q33853042-07584857-A981-4664-9672-AE723F5180CE Q34092740-3AC1AF0A-60BB-4192-9D99-10244C40A1C7 Q34277859-095F6B74-0E4A-456A-ADF4-D4247E9C2E6A Q34363475-24A427EA-DBE9-442C-BAD6-E0784EC4AA58 Q34576418-070DD0DD-06BF-4EF5-85B1-3AC1DA77B169 Q34632746-700DFEAE-7D0C-42A4-875A-1D64802152BB Q34735454-6419A009-D96A-443F-88E3-B7A9CC2C550C Q35285226-EBF75686-ACB4-4C36-A68F-9E182F524E3F Q35334161-12CF27A3-9BC4-45F6-BEA0-9517E0EE76FD Q35775365-4F902B3F-6318-4505-A7C0-DAAB7CA637AC Q35945633-C649BD9F-B71E-4DA2-888D-C0E03BFD57A1 Q35990600-11409C19-24DD-4776-A8A2-5DF41A5E6E1F Q36033650-E6F6CE14-A5A5-4843-B48D-50EDDE1F93D5 Q36078684-12F0CC62-1672-4B37-8C55-F7A8D7B5A3D3 Q36337525-FD3AE204-2C84-4048-AE5E-93AC42A3DECE Q36353787-D13ACF3F-3CFD-452D-9E29-595D340F0263 Q36592268-0F963B7C-DC29-4B2C-91A4-728A7F66FDE9 Q36695912-0BED1674-3E40-4559-8258-84AEF6206148 Q36836566-EB1B5CBA-801B-48D8-B194-1025A9D40651 Q36932748-8ABB50FD-3E05-4043-8A11-3886976EB1FC Q36998284-D0785759-0E9D-4665-B1C8-85954C082C45

P2860

Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis

http://www.wikidata.org/entity/Q28740917

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Multiplexed immunoassay panel ...... isease diagnosis and prognosis

@ast

Multiplexed immunoassay panel ...... isease diagnosis and prognosis

@en

Multiplexed immunoassay panel ...... isease diagnosis and prognosis

@nl

type

label

Multiplexed immunoassay panel ...... isease diagnosis and prognosis

@ast

Multiplexed immunoassay panel ...... isease diagnosis and prognosis

@en

Multiplexed immunoassay panel ...... isease diagnosis and prognosis

@nl

prefLabel

Multiplexed immunoassay panel ...... isease diagnosis and prognosis

@ast

Multiplexed immunoassay panel ...... isease diagnosis and prognosis

@en

Multiplexed immunoassay panel ...... isease diagnosis and prognosis

@nl

P1433

Q28740917-2DF1C8E7-50CB-4CD7-BDB1-4824F91B5D5B

P1476

Q28740917-13DF9CBC-1786-4C03-8E0F-8BFD432DD352

P2093

Q28740917-3154BDD4-3348-45AE-B998-DD295608D607

Q28740917-5B57EA34-7B9B-4DA7-B46F-213453C18A8F

Q28740917-63BC1582-25FC-4433-8A63-FD198CBB145A

Q28740917-741B2A55-924E-45E9-9C3A-4CEF90232D8A

Q28740917-7AEEB370-DA2A-4A33-9231-B03F6F003CBB

Q28740917-84EB5464-A9D1-4B5D-8933-23E1A0E4167F

Q28740917-A55995C4-6B21-4569-8EB6-5FEAAD73B154

Q28740917-E464D2AC-3B29-4188-A2D5-364245F350B0

P2860

Q28740917-00195B29-2870-4FBF-AA5B-6F0C5AFF3A3C

Q28740917-04E40C93-35AC-4AC7-A57B-6D479A63A20E

Q28740917-06E3024E-65D1-4E26-9207-FA38B1815C0E

Q28740917-077EAF87-FBF6-4962-8588-0975FD775898

Q28740917-0B59A02C-F74B-45FB-8F35-447BAF82AFAF

Q28740917-175540E1-7E01-4B69-AB16-9BC779EC6CBF

Q28740917-19E35C8B-9DEB-4842-B443-0EE4B92540B7

Q28740917-1DB21B07-CFF5-4759-8CCF-6287A69C0886

Q28740917-256441E1-2267-4D94-88DE-85B5BE37D3ED

Q28740917-25EFC9DB-4DF5-474B-9611-EAD15387EF5C

P304

Q28740917-28504D07-AA63-4AB6-BAA0-467C115A8A2F

P31

Q28740917-5DCADF0C-63DF-4B9E-B00E-FFCAF1F1E56C

P3181

Q28740917-BA9941B9-88B7-43B5-9A94-2781C0376796

P356

Q28740917-F700E968-57EE-4E9E-BFD4-3E03484475D0

P407

Q28740917-A88862D7-4A03-4E9A-9E95-1DABDF701689

P433

Q28740917-C0209D61-C6A8-4445-B629-B44988259E52

P478

Q28740917-21EDF6DC-BE8C-4087-B573-E5907A89EB9A

P50

Q28740917-7272D23F-9898-4380-A6D1-F43E19586E3A

Q28740917-9345C066-7EB6-41D2-A765-65A069E85335

Q28740917-B0E6C3F9-19C7-4C48-98B8-A2D0F0C49722

P577

Q28740917-5469A900-519F-4FA2-91C8-9F7C6BE7390F

P5875

Q28740917-0FA2F7DF-2810-4B97-BFA7-25E53464DFE9

P698

Q28740917-E0FC998D-1310-408F-9608-5577FD3BE725

P921

Q28740917-57CFD2A3-A23A-46E1-90A3-F69F0CEFD7B8

Q28740917-94a61c16-88f3-42ce-ae66-22b199c5f125

Q28740917-E01BAFA1-16AC-4925-BC4D-733ECE90263A

P932

Q28740917-4872F2C4-2108-4F3B-97B6-D141FCFF24FB

P3181

P356

JOURNAL.PONE.0018850

P1433

P1476

Multiplexed immunoassay panel ...... isease diagnosis and prognosis

@en

P2093

Chengjie Xiong

http://www.w3.org/2001/XMLSchema#string

Eve H Pickering

http://www.w3.org/2001/XMLSchema#string

Holly Soares

http://www.w3.org/2001/XMLSchema#string

Jingxia Liu

http://www.w3.org/2001/XMLSchema#string

Kelly R Bales

http://www.w3.org/2001/XMLSchema#string

Max Kuhn

http://www.w3.org/2001/XMLSchema#string

Rebecca Craig-Schapiro

http://www.w3.org/2001/XMLSchema#string

Richard J Perrin

http://www.w3.org/2001/XMLSchema#string

P2860

Cystatin C modulates cerebral beta-amyloidosis

The role of macrophage migration inhibitory factor in Alzheimer's disease

Biomarkers of Alzheimer's disease

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Mild cognitive impairment: clinical characterization and outcome

Cystatin C inhibits amyloid-beta deposition in Alzheimer's disease mouse models

Genotype and plasma concentration of cystatin C in patients with late-onset Alzheimer disease

Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease

Age-related differences in NFkappaB translocation and Bcl-2/Bax ratio caused by TNFalpha and Abeta42 promote survival in middle-age neurons and death in old neurons

P304

e18850

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

392299

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PONE.0018850

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

David M. Holtzman

P577

2011-04-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51082811

http://www.w3.org/2001/XMLSchema#string

P698

21526197

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

3079734

http://www.w3.org/2001/XMLSchema#string